| Literature DB >> 35182223 |
Chunchun Yao1, Feng Xiang1, Zhangyi Xu2.
Abstract
This paper is a summary of research that looks at the potential of fullerene-like (MO)12 nanoclusters (NCs) in drug-carrying systems using density functional theory. Favipiravir/Zn12O12 (- 34.80 kcal/mol), Favipiravir/Mg12O12 (- 34.98 kcal/mol), and Favipiravir/Be12O12 (- 30.22 kcal/mol) were rated in order of drug adsorption degrees. As a result, Favipiravir attachment to (MgO)12 and (ZnO)12 might be simple, increasing Favipiravir loading efficiency. In addition, the quantum theory of atoms in molecules (QTAIM) assessment was utilized to look at the interactions between molecules. The FMO, ESP, NBO, and Eads reactivity patterns were shown to be in excellent agreement with the QTAIM data. The electrostatic properties of the system with the biggest positive charge on the M atom and the largest Eads were shown to be the best. This system was shown to be the best attraction site for nucleophilic agents. The findings show that (MgO)12 and (ZnO)12 have great carrier potential and may be used in medication delivery.Entities:
Keywords: Density functional theory; Drug delivery; Fullerene; Nucleophilic
Mesh:
Substances:
Year: 2022 PMID: 35182223 PMCID: PMC8857396 DOI: 10.1007/s00894-022-05054-6
Source DB: PubMed Journal: J Mol Model ISSN: 0948-5023 Impact factor: 2.172
Fig. 1The optimized structures of Favipiravir drug and intact (MO)12 NCs
Fig. 2The analysis of ESP and the LUMO and HOMO of the intact (MO)12 NCs
Fig. 3DOS diagrams for the intact (MO)12 NCs
Fig. 4The most stable electronic configurations of the adsorbed Favipiravir on (MO)12 NCs’ surface
Comparison of the values of Eads (kcal/mol) obtained in the solution and gas phase for the complexes of Favipiravir/(MO)12
| Molecule | Gas phase | Solution |
|---|---|---|
| Favipiravir/Be12O12 | − 30.22 | − 41.11 |
| Favipiravir/Mg12O12 | − 34.98 | − 46.65 |
| Favipiravir/Zn12O12 | − 34.80 | − 47.75 |
Fig. 5DOS diagrams for Favipiravir/(MO)12 compounds
Fig. 6Molecular diagram of Favipiravir/(MO)12 compounds. Bond pathways are shown by the lines
The estimated maximum value of absorption wavelength (λ), the transition of dominant contribution for the intact (MO)12 and Favipiravir/(MO)12 and complexes, and oscillator strengths (f)
| complexes | λ (nm) | f0 | Major contribution |
|---|---|---|---|
| Be12O12 | 168.21 | 0.0024 | HOMO → LUMO (71%) |
| Favipiravir/Be12O12 | 294.72 | 0.1241 | HOMO → LUMO (74%) |
| Mg12O12 | 300.31 | 0.0049 | HOMO → LUMO (71%) |
| Favipiravir/Mg12O12 | 411.45 | 0.0035 | HOMO → LUMO (76%) |
| Zn12O12 | 348.98 | 0.0093 | HOMO → LUMO (70%) |
| Favipiravir/Zn12O12 | 372.36 | 0.0032 | HOMO → LUMO (75%) |
The Laplacian of electron density (∇2ρ), electron density (ρ), total electron energy density (H) in a.u., potential energy density (V), kinetic energy density (K), and at BCPs in the Favipiravir-adsorbed compounds by AIM analysis
| Complexes | BCP | ∇2ρ | ρ | K(r) | V(r) | H(r) | K(r)/׀V(r)׀ |
|---|---|---|---|---|---|---|---|
| Favipiravir/Be12O12 | Be18-O35 | 0.431 | 0.0601 | − 0.0067 | − 0.0944 | − 0.0067 | 0.0709 |
| O2-H37 | 0.109 | 0.0341 | 0.0010 | − 0.029 | − 0.0010 | 0.0344 | |
| Favipiravir/Mg12O12 | Mg6-O35 O14-H36 | 0.269 0.154 | 0.0360 0.0522 | − 0.0110 0.0032 | − 0.0452 − 0.0451 | − 0.0110 − 0.0032 | 0.2433 0.0709 |
| Favipiravir/Zn12O12 | Zn17-O35 O8-H37 | 0.319 0.145 | 0.0762 0.0470 | 0.0251 0.0025 | − 0.1303 − 0.0413 | − 0.0251 − 0.0025 | 0.1926 0.0605 |